JP2020523317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523317A5 JP2020523317A5 JP2019567635A JP2019567635A JP2020523317A5 JP 2020523317 A5 JP2020523317 A5 JP 2020523317A5 JP 2019567635 A JP2019567635 A JP 2019567635A JP 2019567635 A JP2019567635 A JP 2019567635A JP 2020523317 A5 JP2020523317 A5 JP 2020523317A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- compound
- pharmaceutical composition
- liquid pharmaceutical
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 229940125904 compound 1 Drugs 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 19
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- 208000037843 metastatic solid tumor Diseases 0.000 claims description 4
- 230000000405 serological effect Effects 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 239000007916 tablet composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- ONIQOQHATWINJY-UHFFFAOYSA-N COc(c(OC)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O Chemical compound COc(c(OC)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 0 COc(c(OC=C*)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O Chemical compound COc(c(OC=C*)cc1ncc2)cc1c2Oc(cc1)ccc1NC(C1(CC1)C(Nc(cc1)ccc1F)=O)=O 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517736P | 2017-06-09 | 2017-06-09 | |
| US62/517,736 | 2017-06-09 | ||
| US201762520768P | 2017-06-16 | 2017-06-16 | |
| US62/520,768 | 2017-06-16 | ||
| PCT/US2018/036703 WO2018227119A1 (en) | 2017-06-09 | 2018-06-08 | Liquid dosage forms to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523317A JP2020523317A (ja) | 2020-08-06 |
| JP2020523317A5 true JP2020523317A5 (https=) | 2021-07-26 |
| JP7249962B2 JP7249962B2 (ja) | 2023-03-31 |
Family
ID=62779087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567635A Active JP7249962B2 (ja) | 2017-06-09 | 2018-06-08 | がんを治療するための液体剤形 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11504362B2 (https=) |
| EP (1) | EP3634413A1 (https=) |
| JP (1) | JP7249962B2 (https=) |
| KR (1) | KR102647794B1 (https=) |
| CN (1) | CN110678180A (https=) |
| AU (1) | AU2018279834B2 (https=) |
| CA (1) | CA3065560A1 (https=) |
| MX (1) | MX2019014298A (https=) |
| UA (1) | UA126402C2 (https=) |
| WO (1) | WO2018227119A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014505109A (ja) * | 2011-02-10 | 2014-02-27 | エクセリクシス， インク． | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
| EP3634413A1 (en) | 2017-06-09 | 2020-04-15 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| UA128476C2 (uk) | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| TW202444365A (zh) | 2023-01-31 | 2024-11-16 | 漢達生技醫藥股份有限公司 | 改良之卡博替尼組合物及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| SG173014A1 (en) * | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| UA111342C2 (uk) | 2010-10-29 | 2016-04-25 | Троікаа Фармасьютікалс Лімітед | Назальні композиції вітаміну b12 |
| KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| GEP201606523B (en) * | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| BR112015001838B1 (pt) | 2012-07-27 | 2022-10-25 | Izumi Technology, Llc | Composição de inibidor de efluxo |
| KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
| IL248408B (en) | 2014-04-25 | 2022-06-01 | Exelixis Inc | A method for treating adenocarcinoma of the lungs |
| ES2929888T3 (es) * | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
| EP3634413A1 (en) | 2017-06-09 | 2020-04-15 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
-
2018
- 2018-06-08 EP EP18735102.8A patent/EP3634413A1/en not_active Withdrawn
- 2018-06-08 CN CN201880035207.9A patent/CN110678180A/zh active Pending
- 2018-06-08 KR KR1020207000409A patent/KR102647794B1/ko active Active
- 2018-06-08 WO PCT/US2018/036703 patent/WO2018227119A1/en not_active Ceased
- 2018-06-08 UA UAA201912200A patent/UA126402C2/uk unknown
- 2018-06-08 CA CA3065560A patent/CA3065560A1/en active Pending
- 2018-06-08 US US16/620,379 patent/US11504362B2/en active Active
- 2018-06-08 MX MX2019014298A patent/MX2019014298A/es unknown
- 2018-06-08 JP JP2019567635A patent/JP7249962B2/ja active Active
- 2018-06-08 AU AU2018279834A patent/AU2018279834B2/en active Active
-
2022
- 2022-10-28 US US17/975,765 patent/US12016854B2/en active Active
-
2024
- 2024-05-10 US US18/661,030 patent/US20240307367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523317A5 (https=) | ||
| JP2022009090A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| RU2640485C2 (ru) | Комбинированное лечение рака | |
| JP2016515628A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JP2013501731A5 (https=) | ||
| JP2024133474A5 (https=) | ||
| JP2004531549A5 (https=) | ||
| JP2019517587A5 (https=) | ||
| JP2010532373A5 (https=) | ||
| JP2019515884A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2019516684A5 (https=) | ||
| JP2019530713A5 (https=) | ||
| JP2018531605A5 (https=) | ||
| JP2021504384A5 (https=) | ||
| JPWO2021178846A5 (https=) | ||
| JP2018530578A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| EP3982967A1 (en) | Methods for treating pulmonary arterial hypertension | |
| CN1283248C (zh) | 包含埃坡霉素的组合及其药学应用 | |
| BR112020009452A2 (pt) | Derivado de cumarina para terapia ou profilaxia de um distúrbio proliferativo celular | |
| RU2358730C2 (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2019531286A5 (https=) |